CCNE2 Overexpression

CI-VAR-00003229Explore in graph →CIViC 3746

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm2
CCNE2 Overexpression	Palbociclib	Predictive	D	Supports Sensitivity Response	3	submitted	EID10184 Breast cancer cell lines derived from T-47D (vector control, overexpress cyclin E1, overexpress cyclin E2) were treated with CDK4/6 inhibitor PD0332991 and CDK2 inhibitor SNS-032 as single agents and … (full text at CIViC) PMID 22564725 · Caldon et al., 2012 · Open in CIViC	civic
CCNE2 Overexpression	CDK Inhibitor SNS-032 + PalbociclibCombination	Predictive	D	Does Not Support Sensitivity Response	3	submitted	EID10185 Breast cancer cell lines derived from T-47D (vector control, overexpress cyclin E1, overexpress cyclin E2) were treated with CDK4/6 inhibitor PD0332991 and CDK2 inhibitor SNS-032 as single agents and … (full text at CIViC) PMID 22564725 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.